eli lilly tirzepatide cease and desist letter demands doctors stop selling copycat weight-loss drugs Eli Lilly just issued a

Participants experienced reductions in body weight, total fat, visceral fat, blood glucose, triglycerides, and cholesterol, alongside an increase in basal metabolic rate, with no reported adverse effects

Under CMS-0057-F (effective January 1, 2026), payers must respond within 7 calendar days for standard requests and 72 hours for urgent/expedited requests

Tirzepatide (Mounjaro, Zepbound) is an FDA-approved medication for type 2 diabetes and chronic weight management that works through dual incretin receptor activation

In clinical trials for chronic weight management (SURMOUNT-1), patients without diabetes lost an average of 15% to 21% of baseline body weight over 72 weeks at maintenance doses of 5 mg to 15 mg weekly